CONMED Q3 sales $275.1M (+10.6% YoY); adjusted EPS $0.77 misses prior year; narrows 2022 guidance

CONMED Corp

2022-Q3 EPS reported -$3.59 revenue$794,605,000

Sales $275.1M +10.6% as reported, +12.1% constant currency; domestic +14.2%, international +6.2% as reported.
GAAP diluted EPS $1.48 (vs $0.47 Q3 2021); adjusted diluted EPS $0.77 (vs $0.80) down 3.8%.
Full-year 2022 revenue guidance narrowed to $1.1B-$1.115B; adjusted EPS guidance lowered to $3.21-$3.28 from $3.25-$3.45.
Closed Biorez acquisition on Aug 9, 2022; integrates with recent In2Bones acquisition.
Orthopedic Surgery sales $118.6M +12.2% as reported; General Surgery $156.5M +9.4%. Single-use +15.1%, capital -8.5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.